Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...

Eli Lilly is spending another $3 billion to bulk ... demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin and the rest of the state as it continues to grow. Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin ...

(AP Photo/Darron Cummings, File) Eli Lilly is spending another $3 billion ... injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined ...

Eli Lilly and Novo Nordisk dominate the market ... Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though ...

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows The FDA approved tirzepatide as Mounjaro for adults with type 2 ...

Eli Lilly and Company announced earlier this week ... Lilly markets tirzepatide as Zepbound for obesity and as Mounjaro for type II diabetes. Though demand for the two drugs remains massive ...